High percentage of false-positive results of cytokeratin 19 RT-PCR in blood:: A model for the analysis of illegitimate gene expression

被引:39
作者
Ko, Y [1 ]
Grünewald, E [1 ]
Totzke, G [1 ]
Klinz, M [1 ]
Fronhoffs, S [1 ]
Gouni-Berthold, I [1 ]
Sachinidis, A [1 ]
Vetter, H [1 ]
机构
[1] Univ Bonn, Med Poliklin, D-53111 Bonn, Germany
关键词
RT PCR; tumor cells; limitation; cytokeratin;
D O I
10.1159/000012126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytokeratin 19 (CK19) RT-PCR is widely used in order to detect circulating tumor cells in peripheral blood and bone marrow. However, increasing amounts of information support the fact that it is also associated with a high percentage of false-positive results. in our study, we not only managed to demonstrate the significant limitations of this method, but were also able to clarify the reasons behind these limitations. We developed a completely novel RT-PCR for CK19 and sequenced an intron at nucleotide (nt) 980 of the CK19 mRNA to exclude DNA contamination. Tumor dilution experiments were performed in order to analyze the specificity and sensitivity of the method. Control experiments using the blood of healthy donors were performed. Tumor cell dilution experiments gave a detection limit of one tumor cell. If tumor cells were mixed with an equal volume of pure mononuclear cells, the detection limit was 1 tumor cell in 10(5) mononuclear cells. RT-PCR of mononuclear cells from healthy blood donors gave false-positive results in 29% of the cases. We conclude that a significant decrease in the sensitivity of CK19 RT-PCR occurs if it is performed in blood cells and that the illegitimate CK19 gene expression in normal cells can lead to false-positive results. These limitations have to be taken into account if RT-PCR is to be used for the detection of tumor cells either in blood or in bone marrow in clinical practice. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 35 条
  • [1] Aihara T, 1997, INT J CANCER, V72, P408, DOI 10.1002/(SICI)1097-0215(19970729)72:3<408::AID-IJC6>3.3.CO
  • [2] 2-M
  • [3] MONOCLONAL-ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN (CEA) IDENTIFIES 2 NEW FORMS OF CROSS-REACTING ANTIGENS OF MOLECULAR-WEIGHT 90,000 AND 160,000 IN NORMAL GRANULOCYTES
    AUDETTE, M
    BUCHEGGER, F
    SCHREYER, M
    MACH, JP
    [J]. MOLECULAR IMMUNOLOGY, 1987, 24 (11) : 1177 - 1186
  • [4] DETECTION OF EPITHELIAL CANCER-CELLS IN PERIPHERAL-BLOOD BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION
    BURCHILL, SA
    BRADBURY, MF
    PITTMAN, K
    SOUTHGATE, J
    SMITH, B
    SELBY, P
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (02) : 278 - 281
  • [5] SENSITIVE DETECTION OF OCCULT BREAST-CANCER BY THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION
    DATTA, YH
    ADAMS, PT
    DROBYSKI, WR
    ETHIER, SP
    TERRY, VH
    ROTH, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 475 - 482
  • [6] THE DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION
    FOSS, AJE
    GUILLE, MJ
    OCCLESTON, NL
    HYKIN, PG
    HUNGERFORD, JL
    LIGHTMAN, S
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (01) : 155 - 159
  • [7] Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients
    Funaki, NO
    Tanaka, J
    Kasamatsu, T
    Ohshio, G
    Hosotani, R
    Okino, T
    Imamura, M
    [J]. LIFE SCIENCES, 1996, 59 (25-26) : 2187 - 2199
  • [8] SPECIFIC DETECTION OF CARCINOEMBRYONIC ANTIGEN-EXPRESSING TUMOR-CELLS IN BONE-MARROW ASPIRATES BY POLYMERASE CHAIN-REACTION
    GERHARD, M
    JUHL, H
    KALTHOFF, H
    SCHREIBER, HW
    WAGENER, C
    NEUMAIER, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 725 - 729
  • [9] DETECTION OF CIRCULATING TUMOR-CELLS IN PATIENTS WITH LOCALIZED AND METASTATIC PROSTATIC-CARCINOMA - CLINICAL IMPLICATIONS
    GHOSSEIN, RA
    SCHER, HI
    GERALD, WL
    KELLY, WK
    CURLEY, T
    AMSTERDAM, A
    ZHANG, ZF
    ROSAI, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1195 - 1200
  • [10] Gunn J, 1996, LAB INVEST, V75, P611